Building on a bioactive ingredient (ligustrazine) from widely used Chinese herbs, Zha et al. profiled the potentials of thirty-two derivatized ligustrazine frameworks against five cancer cell types, namely, tubulin, EGFR, tyrosine receptor kinase (TRK), kafirin (KAF), and B-raf proto-oncogene (BRAF) [66]. This evidence concerns the gene NTRK1 and cancer.